Details

Autor(en) / Beteiligte

• Petersen, Brett W.
• Kabamba, Joelle
• McCollum, Andrea M.
• Lushima, Robert Shongo
• Wemakoy, Emile Okitolonda
• Muyembe Tamfum, Jean-Jacques
• Nguete, Beatrice
• Hughes, Christine M.
• Monroe, Benjamin P.
• Reynolds, Mary G.

Titel

Vaccinating against monkeypox in the Democratic Republic of the Congo

Ist Teil von

• Antiviral research, 2019-02, Vol.162, p.171-177

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2019

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5–5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE®, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations. •Healthcare workers in the rural DRC are at risk of occupationally-acquired infection with monkeypox virus.•Potential hazards of first- and second-generation smallpox vaccines preclude their use in this setting.•We have initiated a study of vaccination of HCWs at risk of MPX with IMVAMUNE, a third-generation smallpox vaccine.•This report describes the methods and results of the study to date.